US 12,433,913 B2
Treatment of acute respiratory disease syndrome (ARDS) with polysulfated polysaccharides
Paul Rennie, Melbourne (AU); and Ravi Krishnan, Melbourne (AU)
Assigned to Paradigm Biopharmaceuticals Ltd., Melbourne (AU)
Appl. No. 17/917,904
Filed by Paradigm Biopharmaceuticals Ltd., Melbourne (AU)
PCT Filed Apr. 9, 2021, PCT No. PCT/AU2021/050327
§ 371(c)(1), (2) Date Oct. 7, 2022,
PCT Pub. No. WO2021/203174, PCT Pub. Date Oct. 14, 2021.
Claims priority of application No. 2020901139 (AU), filed on Apr. 9, 2020.
Prior Publication US 2023/0136817 A1, May 4, 2023
Int. Cl. A61K 31/737 (2006.01); A61P 11/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/737 (2013.01) [A61P 11/00 (2018.01); A61P 31/14 (2018.01)] 14 Claims
 
1. A method for the treatment of pulmonary fibrosis in a human subject resulting from the subject suffering Acute Respiratory Distress Syndrome (ARDS) arising from influenza virus infection, the method comprising the step of administering an effective amount of about 1 to about 2 mg/kg of the subject per dose of a pharmaceutically acceptable salt of pentosan polysulfate (PPS) having a molecular weight of 4,000 to 6,000 daltons and a degree of sulfation of 19% to a subject suffering influenza virus infection.